Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use | All the latest medical news on the portal Medznat.ru. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use

Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use
Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use Subcutaneous Tocilizumab for rheumatoid arthritis patients categorized by baseline glucocorticoid use

What's new?

Glucocorticoid use doesn’t seem to impact the efficacy of introducing subcutaneous Tocilizumab (TCZ-SC) as monotherapy or in combination with concomitant csDMARDs.

Patients with or without prior and continued oral glucocorticoid (GC) treatment show similar efficacy and safety of subcutaneous Tocilizumab (TCZ-SC) as monotherapy or when used in combination with conventional synthetic DMARDs (csDMARDs), according to a single-arm, open-label, common-framework study programme presented in Journal of Rheumatology.

A total of 1804 patients with mild to severe RA among who the biologic or csDMARDs therapies had failed or who were MTX naïve were selected for the analysis.  The participants obtained 162 mg TCZ-SC once-weekly for ⩾24 weeks as monotherapy or in combination with ⩽10 mg/day oral glucocorticoid (GC) or csDMARDs for 24 weeks. Baseline GC use assessed the treatment subgroups for estimating safety and efficacy.

Out of 1804 participants, 208 obtained monotherapy without GC, 145 obtained monotherapy + GC, 721 obtained combination therapy without GC, and 730 obtained combination therapy + GC. The GC subgroups received 5 mg/day median GC dose. The participants who attained clinical remission (DAS28-ESR<2.6) improved similarly from baseline to week 24 in all subgroups. The patient-reported outcomes improvements were also noticed to be similar. On the whole, adverse events were commonly comparable between subgroups, with some small numerical variations between GC and non-GC subgroups. These results manifest equal outcomes of TCZ-SC among all subgroups.

Source:

Rheumatology

Article:

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous Tocilizumab in rheumatoid arthritis

Authors:

Ernest Choy et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: